Fresenius Kabi sells cancer compounding business to NewCo Pharma

Published: 17-Feb-2015
Finance

Will focus on compounding for parenteral nutrition products in Germany going forward


Healthcare company Fresenius Kabi has sold its German subsidiary CFL to NewCo Pharma, a compounding company based in Mannheim, for an undisclosed sum.

Both companies specialise in IV oncology drug compounding.

CFL has compounding centres in Aschaffenberg and Munich as well as compounding pharmacies in Bonn (Compounding Rheinische), Mannheim (Fortune Manufacturing), Osnabruck (Onco Service) and Stuttgart (cas central compounding Baden-Wuerttemberg).

In 2014, CFL had sales of €77m.

Fresenius Kabi says it will remain active in compounding. In Germany, it will focus on parenteral nutrition products, an area that the company says 'offers attractive growth opportunities'.

  • Companies:
  • Fresenius-Kabi
See more

You may also like

Finance

Prange Group and Adragos Pharma to acquire Fresenius Kabi’s manufacturing site in Halden, Norway

Read more
Prange Group and its affiliate Adragos Pharma have announced  the signing of definitive agreements with Fresenius Kabi for the acquisition of the leading sterile  pharmaceutical production site in Halden, Norway

Trending Articles

  1. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
  2. Calibre Scientific acquires DCS to boost immunohistochemistry portfolio The acquisition expands Calibre's immunohistochemistry product and service portfolio across the BACH region
  3. Calibre Scientific acquires RUWAG, a Swiss provider of diagnostics and life sciences products and services Calibre Scientific is pleased to announce the acquisition of RUWAG Handels AG, a provider of diagnostics and life sciences products and services, selling to hospitals, private labs, universities and pharmaceutical companies in Switzerland
  4. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Finance

Prange Group and Adragos Pharma to acquire Fresenius Kabi’s manufacturing site in Halden, Norway

Prange Group and its affiliate Adragos Pharma have announced  the signing of definitive agreements with Fresenius Kabi for the acquisition of the leading sterile  pharmaceutical production site in Halden, Norway
Ingredients

Vifor Pharma enters Chinese joint venture with Fresenius Kabi

Joint venture will bring IV Iron to China to replace the wasteful blood transfusions that are the current prevailing treatment for iron deficiency anaemia
Design & Build

Fresenius Kabi to invest $250 million to expand Melrose Park site in Illinois, US

Building work will start next year at generic injectables plant and will be completed in 2026
Distribution

BD divests Rx business and adds IV solutions

BD and Fresenius Kabi have also signed a 10-year supply and distribution agreement
Finance

Fresenius Kabi expands IV drug business in Latin America

Deal builds on long-term presence in Brazil and creates a strong base for further expansion
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Research & Development

Syncona launches early-stage drug development company, Slingshot Therapeutics

The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
Subscribe now